In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Clal Biotechnology Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TASE:CBI - Analysts future estimates and past financials data (ILS Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	0	-75	-8	-8	N/A
3/31/2024	0	-53	-8	-8	N/A
12/31/2023	0	-31	-9	-9	N/A
9/30/2023	0	-20	-9	-9	N/A
6/30/2023	0	-6	-26	-25	N/A
3/31/2023	-14	-7	-46	-45	N/A
12/31/2022	0	-7	-60	-59	N/A
9/30/2022	77	-78	-71	-70	N/A
6/30/2022	0	-18	-64	-62	N/A
3/31/2022	72	-86	-47	-46	N/A
12/31/2021	0	-28	-43	-41	N/A
9/30/2021	22	103	-44	-42	N/A
6/30/2021	45	89	-33	-29	N/A
3/31/2021	79	109	-39	-36	N/A
12/31/2020	0	186	-36	-33	N/A
9/30/2020	72	-41	-31	-28	N/A
6/30/2020	67	-51	-53	-50	N/A
3/31/2020	127	-144	18	20	N/A
12/31/2019	113	-154	24	27	N/A
9/30/2019	98	-114	22	24	N/A
6/30/2019	83	-81	15	18	N/A
3/31/2019	12	-32	-73	-70	N/A
12/31/2018	13	-45	-90	-87	N/A
9/30/2018	10	-68	-101	-98	N/A
6/30/2018	35	-61	-86	-81	N/A
3/31/2018	36	-36	N/A	-79	N/A
12/31/2017	43	-28	N/A	-91	N/A
9/30/2017	47	-122	N/A	-89	N/A
6/30/2017	27	-176	N/A	-113	N/A
3/31/2017	30	-209	N/A	-110	N/A
12/31/2016	24	-214	N/A	-113	N/A
9/30/2016	22	-149	N/A	-118	N/A
6/30/2016	20	-138	N/A	-116	N/A
3/31/2016	20	-113	N/A	-142	N/A
12/31/2015	25	-118	N/A	-147	N/A
9/30/2015	45	-350	N/A	-129	N/A
6/30/2015	40	-800	N/A	-129	N/A
3/31/2015	33	-747	N/A	-120	N/A
12/31/2014	24	-747	N/A	-116	N/A
9/30/2014	2	-518	N/A	-155	N/A
6/30/2014	1	-65	N/A	-159	N/A
3/31/2014	2	-123	N/A	-156	N/A
12/31/2013	3	-95	N/A	-149	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CBI's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if CBI's earnings are forecast to grow faster than the IL market

High Growth Earnings: Insufficient data to determine if CBI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CBI's revenue is forecast to grow faster than the IL market.

High Growth Revenue: Insufficient data to determine if CBI's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CBI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 06:36
End of Day Share Price	2024/12/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clal Biotechnology Industries Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Pravin Gondhale	Virtua Research Inc.

Clal Biotechnology Industries Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

New major risk - Financial position

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Share price stability

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Third quarter 2022 earnings released: ₪0.015 loss per share (vs ₪0.12 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: ₪0.22 loss per share (vs ₪0.22 loss in 2Q 2021)

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS ₪0.68 (vs ₪0.96 loss in FY 2019)

ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

New 90-day low: ₪1.75

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

New 90-day high: ₪2.24

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day high: ₪2.23

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Novartis AG (SWX:NOVN) reached a definitive agreement to acquire Cadent Therapeutics, Inc. from a group of sellers for approximately $770 million.

ChemomAb Ltd. entered into a definitive merger agreement to acquire Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

New 90-day low: ₪1.58

New 90-day high: ₪1.87

New 90-day high - ₪1.76

BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Neon Therapeutics, Inc. (NasdaqGS:NTGN) from Third Rock Ventures, LLC and others.